Vectans Pharma is proud to announce that Fimea (Finnish Medicines Agency) has granted OTC status to its Lauriad® aciclovir treatment tablet for herpes labialis, Sitavig® 50mg, as a one-per-episode treatment.

"I am pleased to share the news of Sitavig® receiving OTC status in Finland with our partner, Navamedic ASA . This achievement reflects our collective effort and provides a unique opportunity to offer patients access to an innovative treatment," states Vectans Pharma's Director of Regulatory and Industrial Affairs, Jonathan Cohen.

Following Italy and France, Finland is now the third country to grant OTC status upon Lauriad® Aciclovir, while we await further agreements in our global switch projects.